Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

被引：0

作者：

Ivars, David ^{[1
]}

Collado, Rosa ^{[2
]}

Alguero, Carmen ^{[1
]}

Carmen Tormos, M. ^{[1
]}

Diaz, Laura ^{[1
]}

Luis Garcia-Ghnenez, Jose ^{[3
]}

Arrizabalaga, Beatriz ^{[4
]}

Orero, Mayte ^{[2
]}

Perez, Pedro ^{[2
]}

Sanchez, Magdalena ^{[2
]}

Angeles Ruiz, M. ^{[5
]}

Yaguee, Nuria ^{[5
]}

Sancho-Tello, Reyes ^{[6
]}

Regadera, Ana ^{[7
]}

Tormo, Mar ^{[8
]}

Egea, Mercedes ^{[2
]}

Vidal, Elena ^{[2
]}

Enrique O'Connor, J. ^{[1
]}

Saez, Guillermo T. ^{[1
]}

Carbonell, Felix ^{[2
]}

机构：

[1] Univ Valencia, Valencia, Spain

[2] Hosp Gen Univ Valencia, Biomed Diag Ctr, Hematol Serv, Valencia, Spain

[3] Biomed Network Res Ctr Rare Dis, CIBERER, Valencia, Spain

[4] Hosp Cruces, Baracaldo, Spain

[5] Hosp Francesc de Borja, Valencia, Spain

[6] Hosp Arnau Vilanova, Hematol Serv, Valencia, Spain

[7] Hosp Gen Requena, Hematol Serv, Valencia, Spain

[8] Hosp Clin, Valencia, Spain

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.4956.4956

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4956

引用

页数：2

共 50 条

[21] T CELL MEDIATED AUTOLOGOUS CYTOTOXICITY AGAINST HEMATOPOIETIC PRECURSOR CELLS IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
Chamuleau, M. E. D.
Westers, T. M.
Groenland, J.
Dreunen, L.
Zevenbergen, A.
Ossenkoppele, G. J.
van de Loosdrecht, A. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 275 - 275
[22] Treatment of transfusional iron overload with deferasirox in patients with low and intermediate-1 risk MDS: Results from a German multi-center trial
Nolte, F.
Hoechsmann, B.
Luebbert, M.
Platzbecker, U.
Haase, D.
Lueck, A.
Gattermann, N.
Giagounidis, A.
May, C.
Leismann, O.
Junkes, A.
Schumann, C.
Hofmann, W. -K
Schrezenmeier, H.
ONKOLOGIE, 2011, 34 : 290 - 290
[23] Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Remacha, Angel F.
Arrizabalaga, Beatriz
Villegas, Ana
Soledad Duran, Maria
Hermosin, Lourdes
de Paz, Raquel
Garcia, Marta
Diez Campelo, Maria
Sanz, Guillermo
ANNALS OF HEMATOLOGY, 2015, 94 (05) : 779 - 787
[24] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
Platzbecker, Uwe
Symeonidis, Argiris
Goede, Jeroen Simon
Guerci-Bresler, Agnes
Delforge, Michel
Oliva, Esther Natalie
Mayer, Jiri
Badre, Sejal
Mehta, Bhakti
Brandao, Cisio De Oliveira
BLOOD, 2017, 130
[25] Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Ángel F. Remacha
Beatriz Arrizabalaga
Ana Villegas
María Soledad Durán
Lourdes Hermosín
Raquel de Paz
Marta Garcia
Maria Diez Campelo
Guillermo Sanz
Annals of Hematology, 2015, 94 : 779 - 787
[26] Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
Abaza, Yasmin
Hidalgo-Lopez, Juliana E.
Verstovsek, Srdan
Jabbour, Elias
Ravandi, Farhad
Borthakur, Gautam
Estrov, Zeev
Alvarado, Yesid
Burger, Jan
Schneider, Heather
Soltysiak, Kelly A.
Wei, Yue
Kantarjian, Hagop M.
Bueso-Ramos, Carlos E.
Garcia-Manero, Guillermo
LEUKEMIA RESEARCH, 2018, 73 : 78 - 85
[27] Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib
Zarzour, Ahmad
Tabarroki, Ali
Visconte, Valeria
Taftaf, Rokana
Rogers, Heesun J.
Ai, Jing
Papadantonakis, Nikolaos
Lichtin, Alan E.
Saunthararajah, Yogen
Stein, Brady L.
Tiu, Ramon V.
BLOOD, 2014, 124 (21)
[28] Prospective Changes of Cardiac and Hepatic Iron and Cardiac Function in Low and Intermediate-1 Risk MDS Patients
Pepe, Alessia
Meloni, Antonella
Carulli, Giancarlo
Oliva, Esther Natalie
Arcioni, Francesco
Storti, Sergio
Neri, Maria Giovanna
Grassedonio, Emanuele
Renne, Stefania
Restaino, Gennaro
Salvatori, Cristina
Positano, Vincenzo
Rizzo, Michele
BLOOD, 2014, 124 (21)
[29] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Harada, Hironori
Shibayama, Hirohiko
Jang, Jun Ho
Shimazaki, Ryutaro
Mitani, Kinuko
Sawada, Kenichi
Kim, Hyeoung-Joon
BLOOD, 2014, 124 (21)
[30] PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
Cirillo, M.
Carnley, B.
Tan, P.
Tan, D.
Sturm, M.
CYTOTHERAPY, 2018, 20 (05) : S31 - S31

← 1 2 3 4 5 →